Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, 100034, China.
Department of Scientific Research, Peking University First Hospital, Beijing, 100034, China.
Trials. 2020 Nov 4;21(1):912. doi: 10.1186/s13063-020-04830-0.
Asthma is a common chronic airway inflammatory disease. Exacerbations of asthma not only accelerate the progression of the disease but also increase the incidence of hospitalization and death. Studies have shown that air pollution is a high-risk factor for asthma exacerbations. However, few treatment strategies have been recommended to reduce the risk of severe air pollution-related asthma exacerbations.
METHODS/DESIGN: This is a single-centre, prospective, randomized and standard treatment parallel control clinical trial. Seventy-two asthma patients in the nonexacerbation stage according to GINA guidelines 2017 will be recruited and randomized into the rescue intervention strategy (RIS) group and control group. Original treatments for the participants will include no use of inhaled medicine, the use of short-acting β-agonists (SABA) on demand or the use of budesonide/formoterol (160 μg/4.5 μg/dose, 1-2 dose/time, b.i.d.). The rescue intervention strategy for the RIS group will be budesonide/formoterol plus the original treatment until the severe pollution ends (air quality index, AQI < 200). The control group will maintain the original treatment. The follow-up observation period will last 1 year. The primary outcome is the frequency of asthma exacerbations per year. Secondary outcomes include the mean number of unplanned outpatient visits, emergency visits, hospitalizations, medical costs and mortality caused by asthma exacerbations per patient per year.
The results of this trial will provide a novel strategy to guide clinical practice in decreasing the risk of asthma exacerbations under severe air pollution.
ChiCTR ChiCTR1900026757 . Registered on 20 October 2019-retrospectively registered.
哮喘是一种常见的慢性气道炎症性疾病。哮喘发作不仅会加速疾病的进展,还会增加住院和死亡的发生率。研究表明,空气污染是哮喘发作的高危因素。然而,目前很少有治疗策略被推荐用于降低与严重空气污染相关的哮喘发作风险。
方法/设计:这是一项单中心、前瞻性、随机、标准治疗平行对照的临床试验。将根据 2017 年 GINA 指南招募 72 名非发作期哮喘患者,并随机分为救援干预策略(RIS)组和对照组。参与者的原始治疗将包括不使用吸入药物、按需使用短效 β-激动剂(SABA)或使用布地奈德/福莫特罗(160μg/4.5μg/剂量,1-2 次/天,bid.)。RIS 组的救援干预策略将是布地奈德/福莫特罗加原始治疗,直至严重污染结束(空气质量指数,AQI<200)。对照组将维持原始治疗。随访观察期将持续 1 年。主要结局是每年哮喘发作的频率。次要结局包括每年每位患者因哮喘发作而导致的计划外门诊就诊、急诊就诊、住院、医疗费用和死亡的平均次数。
该试验的结果将为降低严重空气污染下哮喘发作风险提供一种新的策略,以指导临床实践。
ChiCTR1900026757. 于 2019 年 10 月 20 日注册-回顾性注册。